2021 MIPS Quality Measures

All 2021 CMS MIPS registry and EHR quality measures can be reported with MDinteractive.  Please check 2021 Clinical Quality Measure (CQM) Specifications to see changes to existing measures made since the release of the 2020 MIPS Measure Specifications. Please check 2021 MIPS Quality Benchmarks to determine how many points each measure can earn for a given performance.

Report 6 measures, including one Outcome or other High Priority measure for 12 months on at least 70% of eligible encounters to possibly earn more than 3 points on a measure.  Note:  Small practices (less than 16 in the practice) can earn 3 points on a measure if at least 1 eligible case is reported.

Tips for choosing MIPS quality measures

  • Start by reviewing the suggestions by specialty available on our website.  Note that CMS has identified “Specialty Measures Sets” for the majority of specialties.
  • You can access our MIPS planning tool within our software by logging into your account, setting up your dashboard with NPI/TIN and clicking on Add/Edit MIPS Plans. After you indicate the categories you will be reporting and clicking “Next”, you will be able to choose from a list of applicable measures or use the filters to narrow down your choices. Note that only measures where you have claims history matching the criteria will appear in this list.  Please contact MDinteractive if you don’t see a measure available on your list.
  • Consider the following factors when deciding which measures to select for MIPS reporting:
    • Clinical conditions usually treated;
    • Types of care typically provided (e.g., preventive, chronic, acute);
    • Settings where care is usually delivered (e.g., office, emergency department [ED], surgical suite);
    • Quality improvement goals;
    • Other quality reporting programs in use or being considered;
    • Only choosing/reporting measures where you have eligible encounters, meaning encounters where the coding on the claims matches the denominator criteria for the measure. 
  • At least 1 of the measures you choose (out of a total of 6) must be designated as either Outcome, or if no applicable Outcome, another High Priority measure.  If a measure with either of these designations is not included in your reporting, CMS will only score 5 out of your 6 measures. The following is an explanation of the measure “types”:
    • Process - Process measures show what doctors and other clinicians do to maintain or improve health, either for healthy people or those diagnosed with a given condition or disease.  These measures usually reflect generally accepted recommendations for clinical practice.  Process measures can tell consumers about medical care they should receive for a given condition or disease, and can help improve health outcomes.
    • Outcome - Outcome measures show how a health care service or intervention influences the health status of patients. Examples: The % of patients who died because of surgery or the rate of surgical complications or hospital acquired infections.  Outcome measures are the result of many factors, some of which may be out of a clinician's control. An Outcome Measure is also classified as High Priority.  CMS asks for an Outcome Measure to be reported as part of the 6 total measures (if one is applicable).
    • High Priority - High priority measures include the following categories of measures:  Outcome, Appropriate Use, Patient Experience, Patient Safety, Efficiency measures, Care coordination. If an Outcome measure (see above) is not applicable, a measure designated as just “high priority” will suffice. 
  • Because you will need to meet completeness requirements for a measure (All insurances, Medicare and non-Medicare) you could choose to select measure(s) with a more defined demographic (meaning that the denominator criteria is limited by ICD-10, age, gender, etc. vs. all eligible patient visits) in order to create a manageable size report.  Note though that measures must be complete and contain at least 20 denominator eligible cases in order to be scored against national benchmarks.
  • Choosing to report Quality measures as a group might be a more efficient way to report.  Here is an example of how this would work:
    • Multi-specialty practice: Let's imagine a practice with one anesthesiologist, one pathologist, one hospitalist, one internist, one dermatologist and one cardiologist. If the providers report MIPS at the individual level, one potentially would need to manage and optimize the performance of 36 different quality measures (6 measures per provider). A group would be able to choose 6 measures that would “cover” the entire practice.   For example, the measure selection could include 2 anesthesia measures, 2 pathology measures and 2 hospitalist measures. There is no need to choose measures that cover all specialties. One just needs to report the patients/visits eligible for the chosen measures.
  • It can be easier to report more specific measures that apply to smaller patient populations. For example, dermatologists could report melanoma measure #137. However, one needs to report a minimum of 20 patients in order to get a score.
  • Consider the reporting frequency of measures such as measure #226 (Tobacco Use: Screening and Cessation Intervention) that only need to be reported once per patient per year versus measures like measure #130 (Documentation of Current Medications in the Medical Record) that need to be reported on each eligible visit. For example, Measure #226 only needs to be reported once on a patient seen for a total of 7 eligible encounters. Measure #130 will need to be reported 7 times in this example.

Understanding Benchmarks*/Scoring when Choosing Your Quality Measures:

  • Be aware of measures which already have high compliance. Medicare calls these "topped-out" measures.
  • Take into consideration that some measures do not currently have benchmarks. As a result, these measures will initially not be scored - even if reported completely. 
  • You should review the MIPS quality measures benchmarks and which measures have no benchmarks or are topped-out.
ID:
001
NQF:
0059
eMeasure ID:
CMS122v9
High Priority:
Yes

2021 MIPS Measure #001: Diabetes: Hemoglobin A1c Poor Control

Percentage of patients 18-75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period

Measure Type
  • Intermediate Outcome
Specifications
Specialty
  • Endocrinology
  • Family Medicine
  • Internal Medicine
  • Nephrology
  • Nutrition/Dietician
  • Preventive Medicine
ID:
005
NQF:
0081
eMeasure ID:
CMS135v9
High Priority:
No

2021 MIPS Measure #005: Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)

Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed ACE inhibitor or ARB or ARNI therapy either within a 12-month period when seen in the outpatient setting OR at each hospital discharge

Measure Type
  • Process
Specifications
Specialty
  • Cardiology
  • Family Medicine
  • Hospitalists
  • Internal Medicine
ID:
006
NQF:
0067
eMeasure ID:
High Priority:
No

2021 MIPS Measure #006: Coronary Artery Disease (CAD): Antiplatelet Therapy

Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease (CAD) seen within a 12-month period who were prescribed aspirin or clopidogrel

Measure Type
  • Process
Specifications
Specialty
  • Cardiology
  • Family Medicine
  • Internal Medicine
  • Skilled Nursing Facility
ID:
007
NQF:
0070
eMeasure ID:
CMS145v9
High Priority:
No

2021 MIPS Measure #007: Coronary Artery Disease (CAD): Beta-Blocker Therapy – Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%)

Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12-month period who also have a prior MI or a current or prior LVEF < 40% who were prescribed beta-blocker therapy

Measure Type
  • Process
Specifications
Specialty
  • Cardiology
  • Family Medicine
  • Internal Medicine
  • Skilled Nursing Facility
ID:
008
NQF:
0083
eMeasure ID:
CMS144v9
High Priority:
No

2021 MIPS Measure #008: Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)

Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed beta-blocker therapy either within a 12-month period when seen in the outpatient setting OR at each hospital discharge

Measure Type
  • Process
Specifications
Specialty
  • Cardiology
  • Family Medicine
  • Hospitalists
  • Internal Medicine
  • Skilled Nursing Facility
ID:
009
NQF:
eMeasure ID:
CMS128v9
High Priority:
No

2021 MIPS Measure #009: Anti-Depressant Medication Management

Percentage of patients 18 years of age and older who were treated with antidepressant medication, had a diagnosis of major depression, and who remained on an antidepressant medication treatment. Two rates are reported:

  1. Percentage of patients who remained on an antidepressant medication for at least 84 days (12 weeks)
  2. Percentage of patients who remained on an antidepressant medication for at least 180 days (6 months)
Measure Type
  • Process
Specifications
Specialty
  • Family Medicine
  • Internal Medicine
  • Mental/Behavioral Health
ID:
012
NQF:
0086
eMeasure ID:
CMS143v9
High Priority:
No

2021 MIPS Measure #012: Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation

Percentage of patients aged 18 years and older with a diagnosis of primary open-angle glaucoma (POAG) who have an optic nerve head evaluation during one or more office visits within 12 months.
 

Measure Type
  • Process
Specifications
Specialty
  • Ophthalmology
ID:
014
NQF:
0087
eMeasure ID:
High Priority:
No

2021 MIPS Measure #014: Age-Related Macular Degeneration (AMD): Dilated Macular Examination

Percentage of patients aged 50 years and older with a diagnosis of age-related macular degeneration (AMD) who had a dilated macular examination performed which included documentation of the presence or absence of macular thickening or geographic atrophy or hemorrhage AND the level of macular degeneration severity during one or more office visits within the 12 month performance period.

Measure Type
  • Process
Specifications
Specialty
  • Ophthalmology
ID:
019
NQF:
0089
eMeasure ID:
CMS142v9
High Priority:
Yes

2021 MIPS Measure #019: Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care

Percentage of patients aged 18 years and older with a diagnosis of diabetic retinopathy who had a dilated macular or fundus exam performed with documented communication to the physician who manages the ongoing care of the patient with diabetes mellitus regarding the findings of the macular or fundus exam at least once within 12 months

Measure Type
  • Process
Specifications
Specialty
  • Ophthalmology
ID:
021
NQF:
0268
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #021: Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second-Generation Cephalosporin

Percentage of surgical patients aged 18 years and older undergoing procedures with the indications for a first OR second-generation cephalosporin prophylactic antibiotic who had an order for a first OR second-generation cephalosporin for antimicrobial prophylaxis

Measure Type
  • Process
Specifications
Specialty
  • General Surgery
  • Neurosurgery
  • Orthopedic Surgery
  • Otolaryngology
  • Plastic Surgery
  • Thoracic Surgery
  • Vascular Surgery
ID:
023
NQF:
0239
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #023: Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)

Percentage of surgical patients aged 18 years and older undergoing procedures for which venous thromboembolism (VTE) prophylaxis is indicated in all patients, who had an order for Low Molecular Weight Heparin (LMWH), Low- Dose Unfractionated Heparin (LDUH), adjusted-dose warfarin, fondaparinux or mechanical prophylaxis to be given within 24 hours prior to incision time or within 24 hours after surgery end time

Measure Type
  • Process
Specifications
Specialty
  • General Surgery
  • Neurosurgery
  • Orthopedic Surgery
  • Otolaryngology
  • Plastic Surgery
  • Thoracic Surgery
  • Urology
  • Vascular Surgery
ID:
024
NQF:
0045
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #024: Communication with the Physician or Other Clinician Managing On-Going Care Post-Fracture for Men and Women Aged 50 Years and Older

Percentage of patients aged 50 years and older treated for a fracture with documentation of communication, between the physician treating the fracture and the physician or other clinician managing the patient’s on-going care, that a fracture occurred and that the patient was or should be considered for osteoporosis treatment or testing. This measure is submitted by the physician who treats the fracture and who therefore is held accountable for the communication

Measure Type
  • Process
Specifications
Specialty
  • Family Medicine
  • Internal Medicine
  • Orthopedic Surgery
  • Preventive Medicine
  • Rheumatology
ID:
039
NQF:
0046
eMeasure ID:
High Priority:
No

2021 MIPS Measure #039: Screening for Osteoporosis for Women Aged 65-85 Years of Age

Percentage of female patients aged 65-85 years of age who ever had a central dual-energy X-ray absorptiometry (DXA) to check for osteoporosis

Measure Type
  • Process
Specifications
Specialty
  • Endocrinology
  • Family Medicine
  • Geriatrics
  • Internal Medicine
  • Preventive Medicine
  • Rheumatology
ID:
044
NQF:
0236
eMeasure ID:
High Priority:
No

2021 MIPS Measure #044: Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery

Percentage of isolated Coronary Artery Bypass Graft (CABG) surgeries for patients aged 18 years and older who received a beta-blocker within 24 hours prior to surgical incision.

Measure Type
  • Process
Specifications
Specialty
  • Anesthesiology
  • Thoracic Surgery
ID:
047
NQF:
0326
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #047: Advance Care Plan

Percentage of patients aged 65 years and older who have an advance care plan or surrogate decision maker documented in the medical record or documentation in the medical record that an advance care plan was discussed but the patient did not wish or was not able to name a surrogate decision maker or provide an advance care plan

Measure Type
  • Process
Specifications
Specialty
  • Cardiology
  • Clinical Social Work
  • Family Medicine
  • Gastroenterology
  • General Surgery
  • Geriatrics
  • Hospitalists
  • Internal Medicine
  • Neurology
  • Obstetrics/Gynecology
  • Oncology/Hematology
  • Orthopedic Surgery
  • Otolaryngology
  • Physical Medicine
  • Preventive Medicine
  • Pulmonology
  • Rheumatology
  • Skilled Nursing Facility
  • Thoracic Surgery
  • Urology
  • Vascular Surgery
ID:
048
NQF:
eMeasure ID:
High Priority:
No

2021 MIPS Measure #048: Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older

Percentage of female patients aged 65 years and older who were assessed for the presence or absence of urinary incontinence within 12 months

Measure Type
  • Process
Specifications
Specialty
  • Family Medicine
  • Geriatrics
  • Internal Medicine
  • Obstetrics/Gynecology
  • Preventive Medicine
  • Urology
ID:
050
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #050: Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older

Percentage of female patients aged 65 years and older with a diagnosis of urinary incontinence with a documented plan of care for urinary incontinence at least once within 12 months

Measure Type
  • Process
Specifications
Specialty
  • Family Medicine
  • Geriatrics
  • Internal Medicine
  • Obstetrics/Gynecology
  • Urology
ID:
052
NQF:
0102
eMeasure ID:
High Priority:
No

2021 MIPS Measure #052: Chronic Obstructive Pulmonary Disease (COPD): Long-Acting Inhaled Bronchodilator Therapy

Percentage of patients aged 18 years and older with a diagnosis of COPD (FEV1/FVC < 70%) and who have an FEV1 less than 60% predicted and have symptoms who were prescribed a long-acting inhaled bronchodilator

Measure Type
  • Process
Specifications
Specialty
  • Pulmonology
ID:
065
NQF:
0069
eMeasure ID:
CMS154v9
High Priority:
Yes

2021 MIPS Measure #065: Appropriate Treatment for Upper Respiratory Infection (URI)

Percentage of episodes for patients 3 months of age and older with a diagnosis of upper respiratory infection (URI) that did not result in an antibiotic dispensing event

Measure Type
  • Process
Specifications
Specialty
  • Family Medicine
  • Otolaryngology
  • Pediatrics
  • Urgent Care
ID:
066
NQF:
eMeasure ID:
CMS146v9
High Priority:
Yes

2021 MIPS Measure #066: Appropriate Testing for Pharyngitis

The percentage of episodes for patients 3 years and older with a diagnosis of pharyngitis that resulted in an antibiotic dispensing event and a group A streptococcus (strep) test

Measure Type
  • Process
Specifications
Specialty
  • Emergency Medicine
  • Family Medicine
  • Pediatrics
  • Urgent Care
ID:
067
NQF:
0377
eMeasure ID:
High Priority:
No

2021 MIPS Measure #067: Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow

Percentage of patients aged 18 years and older with a diagnosis of myelodysplastic syndrome (MDS) or an acute leukemia who had baseline cytogenetic testing performed on bone marrow

Measure Type
  • Process
Specifications
Specialty
  • Oncology/Hematology
ID:
070
NQF:
0379
eMeasure ID:
High Priority:
No

2021 MIPS Measure #070: Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry

Percentage of patients aged 18 years and older, seen within a 12-month reporting period, with a diagnosis of chronic lymphocytic leukemia (CLL) made at any time during or prior to the reporting period who had baseline flow cytometry studies performed and documented in the chart

Measure Type
  • Process
Specifications
Specialty
  • Oncology/Hematology
ID:
076
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #076: Prevention of Central Venous Catheter (CVC) - Related Bloodstream Infections

Percentage of patients, regardless of age, who undergo central venous catheter (CVC) insertion for whom CVC was inserted with all elements of maximal sterile barrier technique, hand hygiene, skin preparation and, if ultrasound is used, sterile ultrasound techniques followed

Measure Type
  • Process
Specifications
Specialty
  • Anesthesiology
  • Hospitalists
  • Interventional Radiology
ID:
093
NQF:
0654
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #093: Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use

Percentage of patients aged 2 years and older with a diagnosis of AOE who were not prescribed systemic antimicrobial therapy

Measure Type
  • Process
Specifications
Specialty
  • Emergency Medicine
  • Family Medicine
  • Internal Medicine
  • Otolaryngology
  • Pediatrics
  • Urgent Care
ID:
102
NQF:
0389
eMeasure ID:
CMS129v10
High Priority:
Yes

2021 MIPS Measure #102: Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients

Percentage of patients, regardless of age, with a diagnosis of prostate cancer at low (or very low) risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy who did not have a bone scan performed at any time since diagnosis of prostate cancer

Measure Type
  • Process
Specifications
Specialty
  • Oncology/Hematology
  • Radiation Oncology
  • Urology
ID:
104
NQF:
0390
eMeasure ID:
High Priority:
No

2021 MIPS Measure #104: Prostate Cancer: Combination Androgen Deprivation Therapy for High Risk or Very High Risk Prostate Cancer

Percentage of patients, regardless of age, with a diagnosis of prostate cancer at high or very high risk of recurrence receiving external beam radiotherapy to the prostate who were prescribed androgen deprivation therapy in combination with external beam radiotherapy to the prostate

Measure Type
  • Process
Specifications
Specialty
  • Urology
ID:
107
NQF:
0104e
eMeasure ID:
CMS161v9
High Priority:
No

2021 MIPS Measure #107: Adult Major Depressive Disorder (MDD): Suicide Risk Assessment

Percentage of patients aged 18 years and older with a diagnosis of major depressive disorder (MDD) with a suicide risk assessment completed during the visit in which a new diagnosis or recurrent episode was identified

Measure Type
  • Process
Specifications
Specialty
  • Emergency Medicine
  • Family Medicine
  • Internal Medicine
  • Mental/Behavioral Health
ID:
110
NQF:
0041
eMeasure ID:
CMS147v10
High Priority:
No

2021 MIPS Measure #110: Preventive Care and Screening: Influenza Immunization

Percentage of patients aged 6 months and older seen for a visit between October 1 and March 31 who received an influenza immunization OR who reported previous receipt of an influenza immunization

Measure Type
  • Process
Specifications
Specialty
  • Allergy/Immunology
  • Cardiology
  • Endocrinology
  • Family Medicine
  • Geriatrics
  • Infectious Disease
  • Internal Medicine
  • Nephrology
  • Obstetrics/Gynecology
  • Oncology/Hematology
  • Otolaryngology
  • Pediatrics
  • Preventive Medicine
  • Pulmonology
  • Rheumatology
  • Skilled Nursing Facility
ID:
111
NQF:
0043
eMeasure ID:
CMS127v9
High Priority:
No

2021 MIPS Measure #111: Pneumococcal Vaccination Status for Older Adults

Percentage of patients 65 years of age and older who have ever received a pneumococcal vaccine

Measure Type
  • Process
Specifications
Specialty
  • Allergy/Immunology
  • Cardiology
  • Endocrinology
  • Family Medicine
  • Geriatrics
  • Infectious Disease
  • Internal Medicine
  • Obstetrics/Gynecology
  • Oncology/Hematology
  • Otolaryngology
  • Preventive Medicine
  • Pulmonology
  • Rheumatology
  • Skilled Nursing Facility
ID:
112
NQF:
2372
eMeasure ID:
CMS125v9
High Priority:
No

2021 MIPS Measure #112: Breast Cancer Screening

Percentage of women 50 - 74 years of age who had a mammogram to screen for breast cancer in the 27 months prior to the end of the measurement period

Measure Type
  • Process
Specifications
Specialty
  • Family Medicine
  • Obstetrics/Gynecology
  • Preventive Medicine
ID:
113
NQF:
0034
eMeasure ID:
CMS130v9
High Priority:
No

2021 MIPS Measure #113: Colorectal Cancer Screening

Percentage of patients 50-75 years of age who had appropriate screening for colorectal cancer

Measure Type
  • Process
Specifications
Specialty
  • Family Medicine
  • Preventive Medicine
ID:
116
NQF:
0058
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #116: Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis

The percentage of episodes for patients ages 3 months and older with a diagnosis of acute bronchitis/bronchiolitis that did not result in an antibiotic dispensing event.

Measure Type
  • Process
Specifications
Specialty
  • Emergency Medicine
  • Family Medicine
  • Internal Medicine
  • Pediatrics
  • Preventive Medicine
  • Urgent Care
ID:
117
NQF:
0055
eMeasure ID:
CMS131v9
High Priority:
No

2021 MIPS Measure #117: Diabetes: Eye Exam

Percentage of patients 18-75 years of age with diabetes and an active diagnosis of retinopathy overlapping the measurement period who had a retinal or dilated eye exam by an eye care professional during the measurement period or diabetics with no diagnosis of retinopathy overlapping the measurement period who had a retinal or dilated eye exam by an eye care professional during the measurement period or in the 12 months prior to the measurement period

Measure Type
  • Process
Specifications
Specialty
  • Endocrinology
  • Family Medicine
  • Internal Medicine
  • Ophthalmology
ID:
118
NQF:
0066
eMeasure ID:
High Priority:
No

2021 MIPS Measure #118: Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)

Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12 month period who also have diabetes OR a current or prior Left Ventricular Ejection Fraction (LVEF) < 40% who were prescribed ACE inhibitor or ARB therapy

Measure Type
  • Process
Specifications
Specialty
  • Cardiology
  • Endocrinology
  • Skilled Nursing Facility
ID:
119
NQF:
0062
eMeasure ID:
CMS134v9
High Priority:
No

2021 MIPS Measure #119: Diabetes: Medical Attention for Nephropathy

The percentage of patients 18-75 years of age with diabetes who had a nephropathy screening test or evidence of nephropathy during the measurement period

Measure Type
  • Process
Specifications
Specialty
  • Endocrinology
  • Family Medicine
  • Internal Medicine
  • Nephrology
  • Preventive Medicine
  • Urology
ID:
126
NQF:
0417
eMeasure ID:
High Priority:
No

2021 MIPS Measure #126: Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy

Percentage of patients aged 18 years and older with a diagnosis of diabetes mellitus who had a neurological examination of their lower extremities within 12 months

Measure Type
  • Process
Specifications
Specialty
  • Endocrinology
  • Family Medicine
  • Internal Medicine
  • Physical Therapy/Occupational Therapy
  • Podiatry
  • Preventive Medicine
ID:
127
NQF:
0416
eMeasure ID:
High Priority:
No

2021 MIPS Measure #127: Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear

Percentage of patients aged 18 years and older with a diagnosis of diabetes mellitus who were evaluated for proper footwear and sizing

Measure Type
  • Process
Specifications
Specialty
  • Physical Therapy/Occupational Therapy
  • Podiatry
ID:
128
NQF:
0421
eMeasure ID:
CMS69v9
High Priority:
No

2021 MIPS Measure #128: Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan

Percentage of patients aged 18 years and older with a BMI documented during the current encounter or within the previous twelve months AND who had a follow-up plan documented if most recent BMI was outside of normal parameters

Measure Type
  • Process
Specifications
Specialty
  • Cardiology
  • Endocrinology
  • Family Medicine
  • Gastroenterology
  • General Surgery
  • Internal Medicine
  • Mental/Behavioral Health
  • Nutrition/Dietician
  • Obstetrics/Gynecology
  • Orthopedic Surgery
  • Otolaryngology
  • Physical Medicine
  • Physical Therapy/Occupational Therapy
  • Podiatry
  • Preventive Medicine
  • Pulmonology
  • Rheumatology
  • Urology
  • Vascular Surgery
ID:
130
NQF:
0419e
eMeasure ID:
CMS68v10
High Priority:
Yes

2021 MIPS Measure #130: Documentation of Current Medications in the Medical Record

Percentage of visits for patients aged 18 years and older for which the eligible professional or eligible clinician attests to documenting a list of current medications using all immediate resources available on the date of the encounter.

Measure Type
  • Process
Specifications
Specialty
  • Allergy/Immunology
  • Audiology
  • Cardiology
  • Clinical Social Work
  • Dermatology
  • Endocrinology
  • Family Medicine
  • Gastroenterology
  • General Surgery
  • Geriatrics
  • Hospitalists
  • Infectious Disease
  • Internal Medicine
  • Mental/Behavioral Health
  • Nephrology
  • Neurology
  • Neurosurgery
  • Nutrition/Dietician
  • Obstetrics/Gynecology
  • Oncology/Hematology
  • Ophthalmology
  • Orthopedic Surgery
  • Otolaryngology
  • Physical Medicine
  • Physical Therapy/Occupational Therapy
  • Plastic Surgery
  • Preventive Medicine
  • Pulmonology
  • Rheumatology
  • Speech/Language Pathology
  • Thoracic Surgery
  • Urgent Care
  • Urology
  • Vascular Surgery
ID:
134
NQF:
0418
eMeasure ID:
CMS2v10
High Priority:
No

2021 MIPS Measure #134: Preventive Care and Screening: Screening for Depression and Follow-Up Plan

Percentage of patients aged 12 years and older screened for depression on the date of the encounter or up to 14 days prior to the date of the encounter using an age-appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of the eligible encounter

Measure Type
  • Process
Specifications
Specialty
  • Audiology
  • Clinical Social Work
  • Endocrinology
  • Family Medicine
  • Internal Medicine
  • Mental/Behavioral Health
  • Neurology
  • Orthopedic Surgery
  • Pediatrics
  • Physical Therapy/Occupational Therapy
  • Preventive Medicine
  • Speech/Language Pathology
ID:
137
NQF:
0650
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #137: Melanoma: Continuity of Care – Recall System

Percentage of patients, regardless of age, with a current diagnosis of melanoma or a history of melanoma whose information was entered, at least once within a 12 month period, into a recall system that includes:

  • A target date for the next complete physical skin exam, AND
  • A process to follow up with patients who either did not make an appointment within the specified timeframe or who missed a scheduled appointment
Measure Type
  • Structure
Specifications
Specialty
  • Dermatology
ID:
138
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #138: Melanoma: Coordination of Care

Percentage of patient visits, regardless of age, with a new occurrence of melanoma that have a treatment plan documented in the chart that was communicated to the physician(s) providing continuing care within one month of diagnosis

Measure Type
  • Process
Specifications
Specialty
  • Dermatology
ID:
141
NQF:
0563
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #141: Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care

Percentage of patients aged 18 years and older with a diagnosis of primary open-angle glaucoma (POAG) whose glaucoma treatment has not failed (the most recent IOP was reduced by at least 15% from the pre-intervention level) OR if the most recent IOP was not reduced by at least 15% from the pre-intervention level, a plan of care was documented within the 12 month performance period

Measure Type
  • Outcome
Specifications
Specialty
  • Ophthalmology
ID:
143
NQF:
0384
eMeasure ID:
CMS157v9
High Priority:
Yes

2021 MIPS Measure #143: Oncology: Medical and Radiation – Pain Intensity Quantified

Percentage of patient visits, regardless of patient age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy in which pain intensity is quantified

Measure Type
  • Process
Specifications
Specialty
  • Oncology/Hematology
  • Radiation Oncology
ID:
144
NQF:
0383
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #144: Oncology: Medical and Radiation – Plan of Care for Pain

Percentage of visits for patients, regardless of age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy who report having pain with a documented plan of care to address pain

Measure Type
  • Process
Specifications
Specialty
  • Oncology/Hematology
  • Radiation Oncology
ID:
145
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #145: Radiology: Exposure Dose Indices or Exposure Time and Number of Images Reported for Procedures Using Fluoroscopy

Final reports for procedures using fluoroscopy that document radiation exposure indices, or exposure time and number of fluorographic images (if radiation exposure indices are not available)

Measure Type
  • Process
Specifications
Specialty
  • Diagnostic Radiology
  • Interventional Radiology
ID:
147
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #147: Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy

Percentage of final reports for all patients, regardless of age, undergoing bone scintigraphy that include physician documentation of correlation with existing relevant imaging studies (e.g., x-ray, Magnetic Resonance Imaging (MRI), Computed Tomography (CT), etc.) that were performed

Measure Type
  • Process
Specifications
Specialty
  • Diagnostic Radiology
ID:
154
NQF:
0101
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #154: Falls: Risk Assessment

Percentage of patients aged 65 years and older with a history of falls that had a risk assessment for falls completed within 12 months

Measure Type
  • Process
Specifications
Specialty
  • Audiology
  • Family Medicine
  • Geriatrics
  • Internal Medicine
  • Neurology
  • Orthopedic Surgery
  • Otolaryngology
  • Physical Medicine
  • Physical Therapy/Occupational Therapy
  • Podiatry
  • Preventive Medicine
  • Skilled Nursing Facility
ID:
155
NQF:
0101
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #155: Falls: Plan of Care

Percentage of patients aged 65 years and older with a history of falls that had a plan of care for falls documented within 12 months

Measure Type
  • Process
Specifications
Specialty
  • Audiology
  • Family Medicine
  • Geriatrics
  • Internal Medicine
  • Neurology
  • Orthopedic Surgery
  • Otolaryngology
  • Physical Medicine
  • Physical Therapy/Occupational Therapy
  • Podiatry
  • Preventive Medicine
  • Skilled Nursing Facility
ID:
164
NQF:
0129
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #164: Coronary Artery Bypass Graft (CABG): Prolonged Intubation

Percentage of patients aged 18 years and older undergoing isolated CABG surgery who require postoperative intubation > 24 hours

Measure Type
  • Outcome
Specifications
Specialty
  • Thoracic Surgery
ID:
167
NQF:
0114
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #167: Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure

Percentage of patients aged 18 years and older undergoing isolated CABG surgery (without pre-existing renal failure) who develop postoperative renal failure or require dialysis

Measure Type
  • Outcome
Specifications
Specialty
  • Thoracic Surgery
ID:
168
NQF:
0115
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #168: Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration

Percentage of patients aged 18 years and older undergoing isolated CABG surgery who require a return to the operating room (OR) during the current hospitalization for mediastinal bleeding with or without tamponade, graft occlusion, valve dysfunction, or other cardiac reason

Measure Type
  • Outcome
Specifications
Specialty
  • Thoracic Surgery
ID:
176
NQF:
eMeasure ID:
High Priority:
No

2021 MIPS Measure #176: Rheumatoid Arthritis (RA): Tuberculosis Screening

If a patient has been newly prescribed a biologic disease-modifying anti-rheumatic drug (DMARD) therapy, then the medical record should indicate TB testing in the preceding 12-month period.

Measure Type
  • Process
Specifications
Specialty
  • Rheumatology
ID:
177
NQF:
eMeasure ID:
High Priority:
No

2021 MIPS Measure #177: Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity

Percentage of patients aged 18 years and older with a diagnosis of rheumatoid arthritis (RA) who have an assessment of disease activity using an ACR-preferred RA disease activity assessment tool at ≥50% of encounters for RA for each patient during the measurement year

Measure Type
  • Process
Specifications
Specialty
  • Rheumatology
ID:
178
NQF:
eMeasure ID:
High Priority:
No

2021 MIPS Measure #178: Rheumatoid Arthritis (RA): Functional Status Assessment

Percentage of patients aged 18 years and older with a diagnosis of rheumatoid arthritis (RA) for whom a functional status assessment was performed at least once within 12 months

Measure Type
  • Process
Specifications
Specialty
  • Orthopedic Surgery
  • Rheumatology
ID:
180
NQF:
eMeasure ID:
High Priority:
No

2021 MIPS Measure #180: Rheumatoid Arthritis (RA): Glucocorticoid Management

Percentage of patients aged 18 years and older with a diagnosis of rheumatoid arthritis (RA) who have been assessed for glucocorticoid use and, for those on prolonged doses of prednisone >5 mg daily (or equivalent) with improvement or no change in disease activity, documentation of glucocorticoid management plan within 12 months

Measure Type
  • Process
Specifications
Specialty
  • Orthopedic Surgery
  • Rheumatology
ID:
181
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #181: Elder Maltreatment Screen and Follow-Up Plan

Percentage of patients aged 65 years and older with a documented elder maltreatment screen using an Elder Maltreatment Screening tool on the date of encounter AND a documented follow-up plan on the date of the positive screen

Measure Type
  • Process
Specifications
Specialty
  • Audiology
  • Clinical Social Work
  • Family Medicine
  • Geriatrics
  • Internal Medicine
  • Mental/Behavioral Health
  • Neurology
  • Nutrition/Dietician
  • Physical Therapy/Occupational Therapy
  • Skilled Nursing Facility
  • Speech/Language Pathology
ID:
182
NQF:
2624
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #182: Functional Outcome Assessment

Percentage of visits for patients aged 18 years and older with documentation of a current functional outcome assessment using a standardized functional outcome assessment tool on the date of the encounter AND documentation of a care plan based on identified functional outcome deficiencies on the date of the identified deficiencies.

Measure Type
  • Process
Specifications
Specialty
  • Audiology
  • Chiropractic Medicine
  • Family Medicine
  • Nephrology
  • Orthopedic Surgery
  • Physical Medicine
  • Physical Therapy/Occupational Therapy
  • Preventive Medicine
  • Speech/Language Pathology
ID:
185
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #185: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use

Percentage of patients aged 18 years and older receiving a surveillance colonoscopy, with a history of prior adenomatous polyp(s) in previous colonoscopy findings, which had an interval of 3 or more years since their last colonoscopy

Measure Type
  • Process
Specifications
Specialty
  • Gastroenterology
ID:
187
NQF:
eMeasure ID:
High Priority:
No

2021 MIPS Measure #187: Stroke and Stroke Rehabilitation: Thrombolytic Therapy

Percentage of patients aged 18 years and older with a diagnosis of acute ischemic stroke who arrive at the hospital within two hours of time last known well and for whom IV alteplase was initiated within three hours of time last known well

Measure Type
  • Process
Specifications
Specialty
  • Emergency Medicine
  • Neurosurgery
ID:
191
NQF:
0565
eMeasure ID:
CMS133v9
High Priority:
Yes

2021 MIPS Measure #191: Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery

Percentage of cataract surgeries for patients aged 18 years and older with a diagnosis of uncomplicated cataract and no significant ocular conditions impacting the visual outcome of surgery and had best-corrected visual acuity of 20/40 or better (distance or near) achieved in the operative eye within 90 days following the cataract surgery

Measure Type
  • Outcome
Specifications
Specialty
  • Ophthalmology
ID:
195
NQF:
0507
eMeasure ID:
High Priority:
No

2021 MIPS Measure #195: Radiology: Stenosis Measurement in Carotid Imaging Reports

Percentage of final reports for carotid imaging studies (neck magnetic resonance angiography [MRA], neck computed tomography angiography [CTA], neck duplex ultrasound, carotid angiogram) performed that include direct or indirect reference to measurements of distal internal carotid diameter as the denominator for stenosis measurement

Measure Type
  • Process
Specifications
Specialty
  • Diagnostic Radiology
ID:
205
NQF:
0409
eMeasure ID:
High Priority:
No

2021 MIPS Measure #205: HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia, Gonorrhea, and Syphilis

Percentage of patients aged 13 years and older with a diagnosis of HIV/AIDS for whom chlamydia, gonorrhea, and syphilis screenings were performed at least once since the diagnosis of HIV infection

Measure Type
  • Process
Specifications
Specialty
  • Infectious Disease
  • Pediatrics
ID:
217
NQF:
0422
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #217: Functional Status Change for Patients with Knee Impairments

A patient-reported outcome measure of risk-adjusted change in functional status for patients aged 14 years+ with knee impairments. The change in functional status (FS) is assessed using the FOTO Lower Extremity Physical Function (LEPF) patient-reported outcome measure (PROM) . The measure is adjusted to patient characteristics known to be associated with FS outcomes (risk adjusted) and used as a performance measure at the patient level, at the individual clinician level, and at the clinic level to assess quality. The measure is available as a computer adaptive test, for reduced patient burden, or a short form (static measure).

Measure Type
  • Outcome
Specifications
Specialty
  • Chiropractic Medicine
  • Orthopedic Surgery
  • Physical Therapy/Occupational Therapy
ID:
218
NQF:
0423
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #218: Functional Status Change for Patients with Hip Impairments

A patient-reported outcome measure of risk-adjusted change in functional status for patients 14 years+ with hip impairments. The change in functional status (FS) is assessed using the FOTO Lower Extremity Physical Function (LEPF) patient-reported outcome measure (PROM) . The measure is adjusted to patient characteristics known to be associated with FS outcomes (risk adjusted) and used as a performance measure at the patient level, at the individual clinician level, and at the clinic level to assess quality. The measure is available as a computer adaptive test, for reduced patient burden, or a short form (static measure).

Measure Type
  • Outcome
Specifications
Specialty
  • Chiropractic Medicine
  • Orthopedic Surgery
  • Physical Therapy/Occupational Therapy
ID:
219
NQF:
0424
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #219: Functional Status Change for Patients with Lower Leg, Foot or Ankle Impairments

A patient-reported outcome measure of risk-adjusted change in functional status for patients 14 years+ with foot, ankle and lower leg impairments. The change in functional status (FS) is assessed using the FOTO Lower Extremity Physical Function (LEPF)patient- reported outcome measure (PROM) . The measure is adjusted to patient characteristics known to be associated with FS outcomes (risk adjusted) and used as a performance measure at the patient level, at the individual clinician level, and at the clinic level to assess quality. The measure is available as a computer adaptive test, for reduced patient burden, or a short form (static measure).

Measure Type
  • Outcome
Specifications
Specialty
  • Chiropractic Medicine
  • Orthopedic Surgery
  • Physical Therapy/Occupational Therapy
ID:
220
NQF:
0425
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #220: Functional Status Change for Patients with Low Back Impairments

A patient-reported outcome measure of risk-adjusted change in functional status for patients 14 years+ with low back impairments. The change in functional status (FS) is assessed using the FOTO Low Back FS patient-reported outcome measure (PROM). The measure is adjusted to patient characteristics known to be associated with FS outcomes (risk adjusted) and used as a performance measure at the patient level, at the individual clinician level, and at the clinic level to assess quality. The measure is available as a computer adaptive test, for reduced patient burden, or a short form (static measure).

Measure Type
  • Outcome
Specifications
Specialty
  • Chiropractic Medicine
  • Orthopedic Surgery
  • Physical Therapy/Occupational Therapy
ID:
221
NQF:
0426
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #221: Functional Status Change for Patients with Shoulder Impairments

A patient-reported outcome measure of risk-adjusted change in functional status for patients 14 years+ with shoulder impairments. The change in functional status (FS) is assessed using the FOTO Shoulder FS patient-reported outcome measure (PROM). The measure is adjusted to patient characteristics known to be associated with FS outcomes (risk adjusted) and used as a performance measure at the patient level, at the individual clinician level, and at the clinic level to assess quality. The measure is available as a computer adaptive test, for reduced patient burden, or a short form (static measure)

Measure Type
  • Outcome
Specifications
Specialty
  • Chiropractic Medicine
  • Orthopedic Surgery
  • Physical Therapy/Occupational Therapy
ID:
222
NQF:
0427
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #222: Functional Status Change for Patients with Elbow, Wrist or Hand Impairments

A patient-reported outcome measure of risk-adjusted change in functional status for patients 14 years+ with elbow, wrist, or hand impairments. The change in functional status (FS) is assessed using the FOTO Elbow/Wrist/Hand FS patient-reported outcome measure (PROM). The measure is adjusted to patient characteristics known to be associated with FS outcomes (risk adjusted) and used as a performance measure at the patient level, at the individual clinician level, and at the clinic level to assess quality. The measure is available as a computer adaptive test, for reduced patient burden, or a short form (static measure).

Measure Type
  • Outcome
Specifications
Specialty
  • Chiropractic Medicine
  • Orthopedic Surgery
  • Physical Therapy/Occupational Therapy
ID:
225
NQF:
0509
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #225: Radiology: Reminder System for Screening Mammograms

Percentage of patients undergoing a screening mammogram whose information is entered into a reminder system with a target due date for the next mammogram

Measure Type
  • Structure
Specifications
Specialty
  • Diagnostic Radiology
ID:
226
NQF:
0028
eMeasure ID:
CMS138v9
High Priority:
No

2021 MIPS Measure #226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention

Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 12 months AND who received tobacco cessation intervention if identified as a tobacco user

Measure Type
  • Process
Specifications
Specialty
  • Allergy/Immunology
  • Audiology
  • Cardiology
  • Clinical Social Work
  • Dermatology
  • Endocrinology
  • Family Medicine
  • Gastroenterology
  • General Surgery
  • Internal Medicine
  • Mental/Behavioral Health
  • Neurology
  • Neurosurgery
  • Obstetrics/Gynecology
  • Oncology/Hematology
  • Ophthalmology
  • Orthopedic Surgery
  • Otolaryngology
  • Physical Medicine
  • Physical Therapy/Occupational Therapy
  • Plastic Surgery
  • Podiatry
  • Preventive Medicine
  • Pulmonology
  • Rheumatology
  • Speech/Language Pathology
  • Thoracic Surgery
  • Urgent Care
  • Urology
  • Vascular Surgery
ID:
236
NQF:
0018
eMeasure ID:
CMS165v9
High Priority:
Yes

2021 MIPS Measure #236: Controlling High Blood Pressure

Percentage of patients 18 - 85 years of age who had a diagnosis of hypertension overlapping the measurement period or the year prior to the measurement period, and whose most recent blood pressure was adequately controlled (< 140/90 mmHg) during the measurement period

Measure Type
  • Intermediate Outcome
Specifications
Specialty
  • Cardiology
  • Endocrinology
  • Family Medicine
  • Internal Medicine
  • Obstetrics/Gynecology
  • Pulmonology
  • Rheumatology
  • Vascular Surgery
ID:
238
NQF:
0022
eMeasure ID:
CMS156v9
High Priority:
Yes

2021 MIPS Measure #238: Use of High-Risk Medications in the Elderly

Percentage of patients 65 years of age and older who were ordered at least two of the same high-risk medications.

Measure Type
  • Process
Specifications
Specialty
  • Allergy/Immunology
  • Cardiology
  • Family Medicine
  • Geriatrics
  • Internal Medicine
  • Ophthalmology
  • Pulmonology
  • Rheumatology
  • Skilled Nursing Facility
ID:
239
NQF:
eMeasure ID:
CMS155v9
High Priority:
No

2021 MIPS Measure #239: Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents

Percentage of patients 3-17 years of age who had an outpatient visit with a Primary Care Physician (PCP) or Obstetrician/Gynecologist (OB/GYN) and who had evidence of the following during the measurement period. Three rates are reported.

- Percentage of patients with height, weight, and body mass index (BMI) percentile documentation
- Percentage of patients with counseling for nutrition
- Percentage of patients with counseling for physical activity

Measure Type
  • Process
Specifications
Specialty
  • Nutrition/Dietician
  • Pediatrics
ID:
240
NQF:
eMeasure ID:
CMS117v9
High Priority:
No

2021 MIPS Measure #240: Childhood Immunization Status

Percentage of children 2 years of age who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV), one measles, mumps and rubella (MMR); three or four H influenza type B (HiB); three hepatitis B (Hep B); one chicken pox (VZV); four pneumococcal conjugate (PCV); one hepatitis A (Hep A); two or three rotavirus (RV); and two influenza (flu) vaccines by their second birthday.

Measure Type
  • Process
Specifications
Specialty
  • Pediatrics
ID:
243
NQF:
0643
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #243: Cardiac Rehabilitation Patient Referral from an Outpatient Setting

Percentage of patients evaluated in an outpatient setting who within the previous 12 months have experienced an acute myocardial infarction (MI), coronary artery bypass graft (CABG) surgery, a percutaneous coronary intervention (PCI), cardiac valve surgery, or cardiac transplantation, or who have chronic stable angina (CSA) and have not already participated in an early outpatient cardiac rehabilitation/secondary prevention (CR) program for the qualifying event/diagnosis who were referred to a CR program

Definition:

Referral - A referral is defined as an official communication between the health care provider and the patient to recommend and carry out a referral order to an outpatient CR program. This includes the provision of all necessary information to the patient that will allow the patient to enroll in an outpatient CR program. This also includes a written or electronic communication between the healthcare provider or healthcare system and the cardiac rehabilitation program that includes the patient's enrollment information for the program. A hospital discharge summary or office note may potentially be formatted to include the necessary patient information to communicate to the CR program (the patient’s cardiovascular history, testing, and treatments, for instance). According to standards of practice for cardiac rehabilitation programs, care coordination communications are sent to the referring provider, including any issues regarding treatment changes, adverse treatment responses, or new non-emergency condition (new symptoms, patient care questions, etc.) that need attention by the referring provider. These communications also include a progress report once the patient has completed the program. All communications must maintain an appropriate level of confidentiality as outlined by the 1996 Health Insurance Portability and Accountability Act (HIPAA).

NOTE: A patient with a qualifying diagnosis should have a referral to CR within the subsequent 12 months. In the event that the patient has a second (recurrent) qualifying event before the original 12 month “referral” period has ended, a new 12 month “referral” period for CR referral starts at the time of the second qualifying event, since the patient again becomes eligible for CR at that time.

Measure Type
  • Process
Specifications
Specialty
  • Cardiology
  • Family Medicine
  • Internal Medicine
ID:
249
NQF:
1854
eMeasure ID:
High Priority:
No

2021 MIPS Measure #249: Barrett's Esophagus

Percentage of esophageal biopsy reports that document the presence of Barrett’s mucosa that also include a statement about dysplasia

Measure Type
  • Process
Specifications
Specialty
  • Pathology
ID:
250
NQF:
1853
eMeasure ID:
High Priority:
No

2021 MIPS Measure #250: Radical Prostatectomy Pathology Reporting

Percentage of radical prostatectomy pathology reports that include the pT category, the pN category, the Gleason score and a statement about margin status

Measure Type
  • Process
Specifications
Specialty
  • Oncology/Hematology
  • Pathology
ID:
254
NQF:
0651
eMeasure ID:
High Priority:
No

2021 MIPS Measure #254: Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain

Percentage of pregnant female patients aged 14 to 50 who present to the emergency department (ED) with a chief complaint of abdominal pain or vaginal bleeding who receive a trans-abdominal or trans-vaginal ultrasound to determine pregnancy location

Measure Type
  • Process
Specifications
Specialty
  • Emergency Medicine
ID:
258
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #258: Rate of Open Repair of Small or Moderate Non-Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7)

Percent of patients undergoing open repair of small or moderate sized non-ruptured infrarenal abdominal aortic aneurysms (AAA) who do not experience a major complication (discharge to home no later than post-operative day #7)

Measure Type
  • Outcome
Specifications
Specialty
  • Vascular Surgery
ID:
259
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #259: Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #2)

Percent of patients undergoing endovascular repair of small or moderate non-ruptured infrarenal abdominal aortic aneurysms (AAA) that do not experience a major complication (discharged to home no later than post-operative day #2)

Measure Type
  • Outcome
Specifications
Specialty
  • Vascular Surgery
ID:
260
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #260: Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home by Post-Operative Day #2)

Percent of asymptomatic patients undergoing Carotid Endarterectomy (CEA) who are discharged to home no later than post-operative day #2.

Measure Type
  • Outcome
Specifications
Specialty
  • Neurosurgery
  • Vascular Surgery
ID:
261
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #261: Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness

Percentage of patients aged birth and older referred to a physician (preferably a physician specially trained in disorders of the ear) for an otologic evaluation subsequent to an audiologic evaluation after presenting with acute or chronic dizziness

Measure Type
  • Process
Specifications
Specialty
  • Audiology
ID:
264
NQF:
eMeasure ID:
High Priority:
No

2021 MIPS Measure #264: Sentinel Lymph Node Biopsy for Invasive Breast Cancer

The percentage of clinically node negative (clinical stage T1N0M0 or T2N0M0) breast cancer patients before or after neoadjuvant systemic therapy, who undergo a sentinel lymph node (SLN) procedure

Measure Type
  • Process
Specifications
Specialty
  • General Surgery
ID:
265
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #265: Biopsy Follow-Up

Percentage of new patients whose biopsy results have been reviewed and communicated to the primary care/referring physician and patient

Measure Type
  • Process
Specifications
Specialty
  • Dermatology
  • Obstetrics/Gynecology
  • Otolaryngology
  • Urology
ID:
268
NQF:
1814
eMeasure ID:
High Priority:
No

2021 MIPS Measure #268: Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy

Percentage of all patients of childbearing potential (12 years and older) diagnosed with epilepsy who were counseled at least once a year about how epilepsy and its treatment may affect contraception and pregnancy

Measure Type
  • Process
Specifications
Specialty
  • Neurology
ID:
275
NQF:
eMeasure ID:
High Priority:
No

2021 MIPS Measure #275: Inflammatory Bowel Disease (IBD): Assessment of Hepatitis B Virus (HBV) Status

Percentage of patients with a diagnosis of inflammatory bowel disease (IBD) who had Hepatitis B Virus (HBV) status assessed and results interpreted prior to initiating anti-TNF (tumor necrosis factor) therapy

Measure Type
  • Process
Specifications
Specialty
  • Gastroenterology
ID:
277
NQF:
eMeasure ID:
High Priority:
No

2021 MIPS Measure #277: Sleep Apnea: Severity Assessment at Initial Diagnosis

Percentage of patients aged 18 years and older with a diagnosis of obstructive sleep apnea who had an apnea hypopnea index (AHI) or a respiratory disturbance index (RDI) measured at the time of initial diagnosis

Measure Type
  • Process
Specifications
Specialty
  • Internal Medicine
  • Neurology
  • Otolaryngology
  • Pulmonology
ID:
279
NQF:
eMeasure ID:
High Priority:
No

2021 MIPS Measure #279: Sleep Apnea: Assessment of Adherence to Positive Airway Pressure Therapy

Percentage of visits for patients aged 18 years and older with a diagnosis of obstructive sleep apnea who were prescribed positive airway pressure therapy who had documentation that adherence to positive airway pressure therapy was objectively measured

Measure Type
  • Process
Specifications
Specialty
  • Internal Medicine
  • Neurology
  • Otolaryngology
  • Pulmonology
ID:
281
NQF:
2872e
eMeasure ID:
CMS149v9
High Priority:
No

2021 MIPS Measure #281: Dementia: Cognitive Assessment

Percentage of patients, regardless of age, with a diagnosis of dementia for whom an assessment of cognition is performed and the results reviewed at least once within a 12-month period

Measure Type
  • Process
Specifications
Specialty
  • Clinical Social Work
  • Geriatrics
  • Mental/Behavioral Health
  • Neurology
  • Physical Therapy/Occupational Therapy
ID:
282
NQF:
eMeasure ID:
High Priority:
No

2021 MIPS Measure #282: Dementia: Functional Status Assessment

Percentage of patients with dementia for whom an assessment of functional status was performed at least once in the last 12 months

Measure Type
  • Process
Specifications
Specialty
  • Clinical Social Work
  • Geriatrics
  • Mental/Behavioral Health
  • Neurology
ID:
283
NQF:
eMeasure ID:
High Priority:
No

2021 MIPS Measure #283: Dementia Associated Behavioral and Psychiatric Symptoms Screening and Management

Percentage of patients with dementia for whom there was a documented screening for behavioral and psychiatric symptoms, including depression, and for whom, if symptoms screening was positive, there was also documentation of recommendations for management in the last 12 months

Measure Type
  • Process
Specifications
Specialty
  • Clinical Social Work
  • Geriatrics
  • Mental/Behavioral Health
  • Neurology
  • Physical Therapy/Occupational Therapy
ID:
286
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #286: Dementia: Safety Concern Screening and Follow-Up for Patients with Dementia

Percentage of patients with dementia or their caregiver(s) for whom there was a documented safety concerns screening in two domains of risk: 1) dangerousness to self or others and 2) environmental risks; and if safety concerns screening was positive in the last 12 months, there was documentation of mitigation recommendations, including but not limited to referral to other resources

Measure Type
  • Process
Specifications
Specialty
  • Clinical Social Work
  • Geriatrics
  • Mental/Behavioral Health
  • Neurology
  • Physical Therapy/Occupational Therapy
ID:
288
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #288: Dementia: Education and Support of Caregivers for Patients with Dementia

Percentage of patients with dementia whose caregiver(s) were provided with education on dementia disease management and health behavior changes AND were referred to additional resources for support in the last 12 months

Measure Type
  • Process
Specifications
Specialty
  • Clinical Social Work
  • Geriatrics
  • Mental/Behavioral Health
  • Neurology
  • Physical Therapy/Occupational Therapy
ID:
290
NQF:
eMeasure ID:
High Priority:
No

2021 MIPS Measure #290: Parkinson’s Disease: Psychiatric Symptoms Assessment for Patients with Parkinson’s Disease

Percentage of all patients with a diagnosis of Parkinson’s Disease [PD] who were assessed for psychiatric symptoms once in the past 12 months

Measure Type
  • Process
Specifications
Specialty
  • Neurology
ID:
291
NQF:
eMeasure ID:
High Priority:
No

2021 MIPS Measure #291: Parkinson’s Disease: Cognitive Impairment or Dysfunction Assessment for Patients with Parkinson’s Disease

Percentage of all patients with a diagnosis of Parkinson’s Disease [PD] who were assessed for cognitive impairment or dysfunction once in the past 12 months

Measure Type
  • Process
Specifications
Specialty
  • Neurology
ID:
293
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #293: Parkinson’s Disease: Rehabilitative Therapy Options

Percentage of all patients with a diagnosis of Parkinson’s Disease (or caregiver(s), as appropriate) who had rehabilitative therapy options (i.e., physical, occupational, and speech therapy) discussed once in the past 12 months

Measure Type
  • Process
Specifications
Specialty
  • Neurology
ID:
303
NQF:
1536
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #303: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery

Percentage of patients aged 18 years and older who had cataract surgery and had improvement in visual function achieved within 90 days following the cataract surgery, based on completing a pre-operative and post-operative visual function survey

Measure Type
  • Outcome
Specifications
Specialty
  • Ophthalmology
ID:
304
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #304: Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery

Percentage of patients aged 18 years and older who had cataract surgery and were satisfied with their care within 90 days following the cataract surgery, based on completion of the Consumer Assessment of Healthcare Providers and Systems Surgical Care Survey

Measure Type
  • Outcome
Specifications
Specialty
  • Ophthalmology
ID:
305
NQF:
eMeasure ID:
CMS137v9
High Priority:
Yes

2021 MIPS Measure #305: Initiation and Engagement of Alcohol and Other Drug Dependence Treatment

Percentage of patients 13 years of age and older with a new episode of alcohol or other drug abuse or (AOD) dependence who received the following. Two rates are reported.

a. Percentage of patients who initiated treatment including either an intervention or medication for the treatment of AOD abuse or dependence within 14 days of the diagnosis
b. Percentage of patients who engaged in ongoing treatment including two additional interventions or a medication for the treatment of AOD abuse or dependence within 34 days of the initiation visit. For patients who initiated treatment with a medication, at least one of the two engagement events must be a treatment intervention.

Measure Type
  • Process
Specifications
Specialty
  • Family Medicine
  • Internal Medicine
  • Pediatrics
ID:
309
NQF:
eMeasure ID:
CMS124v9
High Priority:
No

2021 MIPS Measure #309: Cervical Cancer Screening

Percentage of women 21-64 years of age who were screened for cervical cancer using either of the following criteria:

* Women age 21-64 who had cervical cytology performed every 3 years
* Women age 30-64 who had cervical cytology/human papillomavirus (HPV) co-testing performed every 5 years

Measure Type
  • Process
Specifications
Specialty
  • Family Medicine
  • Internal Medicine
  • Obstetrics/Gynecology
ID:
310
NQF:
eMeasure ID:
CMS153v9
High Priority:
No

2021 MIPS Measure #310: Chlamydia Screening for Women

Percentage of women 16-24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement period

Measure Type
  • Process
Specifications
Specialty
  • Obstetrics/Gynecology
  • Pediatrics
ID:
317
NQF:
eMeasure ID:
CMS22v9
High Priority:
No

2021 MIPS Measure #317: Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented

Percentage of patient visits for patients aged 18 years and older seen during the measurement period who were screened for high blood pressure AND a recommended follow-up plan is documented, as indicated, if blood pressure is pre-hypertensive or hypertensive

Measure Type
  • Process
Specifications
Specialty
  • Allergy/Immunology
  • Cardiology
  • Dermatology
  • Emergency Medicine
  • Family Medicine
  • Gastroenterology
  • General Surgery
  • Internal Medicine
  • Mental/Behavioral Health
  • Nephrology
  • Neurology
  • Obstetrics/Gynecology
  • Oncology/Hematology
  • Orthopedic Surgery
  • Otolaryngology
  • Physical Medicine
  • Plastic Surgery
  • Preventive Medicine
  • Rheumatology
  • Skilled Nursing Facility
  • Thoracic Surgery
  • Urgent Care
  • Urology
  • Vascular Surgery
ID:
318
NQF:
0101
eMeasure ID:
CMS139v9
High Priority:
Yes

2021 MIPS Measure #318: Falls: Screening for Future Fall Risk

Percentage of patients 65 years of age and older who were screened for future fall risk during the measurement period

Measure Type
  • Process
Specifications
Specialty
  • Audiology
  • Family Medicine
  • Internal Medicine
  • Nephrology
  • Orthopedic Surgery
  • Otolaryngology
  • Physical Therapy/Occupational Therapy
  • Podiatry
ID:
320
NQF:
0658
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #320: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients

Percentage of patients aged 50 to 75 years of age receiving a screening colonoscopy without biopsy or polypectomy who had a recommended follow-up interval of at least 10 years for repeat colonoscopy documented in their colonoscopy report

Measure Type
  • Process
Specifications
Specialty
  • Gastroenterology
ID:
322
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #322: Cardiac Stress Imaging Not Meeting Appropriate Use Criteria:Preoperative Evaluation in Low-Risk Surgery Patients

Percentage of stress single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI), stress echocardiogram (ECHO), cardiac computed tomography angiography (CCTA), or cardiac magnetic resonance (CMR) performed in low-risk surgery patients 18 years or older for preoperative evaluation during the 12-month submission period

Measure Type
  • Efficiency
Specifications
Specialty
  • Cardiology
ID:
323
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #323: Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI)

Percentage of all stress single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI), stress echocardiogram (ECHO), cardiac computed tomography angiography (CCTA), and cardiovascular magnetic resonance (CMR) performed in patients aged 18 years and older routinely after percutaneous coronary intervention (PCI), with reference to timing of test after PCI and symptom status

Measure Type
  • Efficiency
Specifications
Specialty
  • Cardiology
ID:
324
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #324: Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients

Percentage of all stress single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI), stress echocardiogram (ECHO), cardiac computed tomography angiography (CCTA), and cardiovascular magnetic resonance (CMR) performed in asymptomatic, low coronary heart disease (CHD) risk patients 18 years and older for initial detection and risk assessment

Measure Type
  • Efficiency
Specifications
Specialty
  • Cardiology
ID:
326
NQF:
1525
eMeasure ID:
High Priority:
No

2021 MIPS Measure #326: Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy

Percentage of patients aged 18 years and older with nonvalvular atrial fibrillation (AF) or atrial flutter who were prescribed warfarin OR another FDA-approved oral anticoagulant drug for the prevention of thromboembolism during the measurement period

Measure Type
  • Process
Specifications
Specialty
  • Cardiology
  • Family Medicine
  • Internal Medicine
  • Skilled Nursing Facility
ID:
331
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #331: Adult Sinusitis: Antibiotic Prescribed for Acute Viral Sinusitis (Overuse)

Percentage of patients, aged 18 years and older, with a diagnosis of acute viral sinusitis who were prescribed an antibiotic within 10 days after onset of symptoms

Measure Type
  • Process
Specifications
Specialty
  • Allergy/Immunology
  • Emergency Medicine
  • Family Medicine
  • Internal Medicine
  • Otolaryngology
  • Urgent Care
ID:
332
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #332: Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin With or Without Clavulanate Prescribed for Patients with Acute Bacterial Sinusitis (Appropriate Use)

Percentage of patients aged 18 years and older with a diagnosis of acute bacterial sinusitis that were prescribed amoxicillin, with or without clavulanate, as a first line antibiotic at the time of diagnosis

Measure Type
  • Process
Specifications
Specialty
  • Allergy/Immunology
  • Emergency Medicine
  • Family Medicine
  • Internal Medicine
  • Otolaryngology
  • Urgent Care
ID:
335
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #335: Maternity Care: Elective Delivery or Early Induction Without Medical Indication at < 39 Weeks (Overuse)

Percentage of patients, regardless of age, who gave birth during a 12-month period who delivered a live singleton at < 39 weeks of gestation completed who had elective deliveries by cesarean section (C-section), or early inductions of labor, without medical indication.

Measure Type
  • Outcome
Specifications
Specialty
  • Obstetrics/Gynecology
ID:
336
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #336: Maternity Care: Postpartum Follow-up and Care Coordination

Percentage of patients, regardless of age, who gave birth during a 12-month period who were seen for postpartum care before or at 8 weeks of giving birth and received the following at a postpartum visit: breast-feeding evaluation and education, postpartum depression screening, postpartum glucose screening for gestational diabetes patients, family and contraceptive planning counseling, tobacco use screening and cessation education, healthy lifestyle behavioral advice, and an immunization review and update

Measure Type
  • Process
Specifications
Specialty
  • Obstetrics/Gynecology
ID:
337
NQF:
eMeasure ID:
High Priority:
No

2021 MIPS Measure #337: Psoriasis: Tuberculosis (TB) Prevention for Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis on a Biological Immune Response Modifier

Percentage of patients, regardless of age, with psoriasis, psoriatic arthritis and/or rheumatoid arthritis on a biological immune response modifier whose providers are ensuring active tuberculosis prevention either through negative standard tuberculosis screening tests or are reviewing the patient’s history to determine if they have had appropriate management for a recent or prior positive test

Measure Type
  • Process
Specifications
Specialty
  • Dermatology
  • Family Medicine
  • Internal Medicine
ID:
338
NQF:
2082
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #338: HIV Viral Load Suppression

The percentage of patients, regardless of age, with a diagnosis of HIV with a HIV viral load less than 200 copies/mL at last HIV viral load test during the measurement year

Measure Type
  • Outcome
Specifications
Specialty
  • Allergy/Immunology
  • Family Medicine
  • Infectious Disease
  • Internal Medicine
ID:
340
NQF:
2079
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #340: HIV Medical Visit Frequency

Percentage of patients, regardless of age, with a diagnosis of HIV who had at least one medical visit in each 6 month period of the 24 month measurement period, with a minimum of 60 days between medical visits.

Measure Type
  • Process
Specifications
Specialty
  • Allergy/Immunology
  • Infectious Disease
ID:
342
NQF:
0209
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #342: Pain Brought Under Control Within 48 Hours

Patients aged 18 and older who report being uncomfortable because of pain at the initial assessment (after admission to palliative care services) who report pain was brought to a comfortable level within 48 hours

Measure Type
  • Outcome
Specifications
Specialty
  • Family Medicine
  • Internal Medicine
ID:
344
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #344: : Rate of Carotid Artery Stenting (CAS) for Asymptomatic Patients, Without Major Complications (Discharged to Home by Post-Operative Day #2)

Percent of asymptomatic patients undergoing CAS who are discharged to home no later than post-operative day #2

Measure Type
  • Outcome
Specifications
Specialty
  • Cardiology
  • Neurosurgery
  • Vascular Surgery
ID:
350
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #350: : Total Knee Replacement: Shared Decision-Making: Trial of Conservative (Non-surgical) Therapy

Percentage of patients regardless of age undergoing a total knee replacement with documented shared decisionmaking with discussion of conservative (non-surgical) therapy (e.g., non-steroidal anti-inflammatory drug (NSAIDs), analgesics, weight loss, exercise, injections) prior to the procedure.

Measure Type
  • Process
Specifications
Specialty
  • Orthopedic Surgery
ID:
351
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #351: Total Knee Replacement: Venous Thromboembolic and Cardiovascular Risk Evaluation

Percentage of patients regardless of age undergoing a total knee replacement who are evaluated for the presence or absence of venous thromboembolic and cardiovascular risk factors within 30 days prior to the procedure (e.g., History of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Myocardial Infarction (MI), Arrhythmia and Stroke)

Measure Type
  • Process
Specifications
Specialty
  • Orthopedic Surgery
ID:
354
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #354: Anastomotic Leak Intervention

Percentage of patients aged 18 years and older who required an anastomotic leak intervention following gastric bypass or colectomy surgery

Measure Type
  • Outcome
Specifications
Specialty
  • General Surgery
ID:
355
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #355: Unplanned Reoperation within the 30 Day Postoperative Period

Percentage of patients aged 18 years and older who had any unplanned reoperation within the 30 day postoperative period

Measure Type
  • Outcome
Specifications
Specialty
  • General Surgery
  • Plastic Surgery
ID:
356
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #356: Unplanned Hospital Readmission within 30 Days of Principal Procedure

Percentage of patients aged 18 years and older who had an unplanned hospital readmission within 30 days of principal procedure

Measure Type
  • Outcome
Specifications
Specialty
  • General Surgery
  • Plastic Surgery
ID:
357
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #357: Surgical Site Infection (SSI)

Percentage of patients aged 18 years and older who had a surgical site infection (SSI)

Measure Type
  • Outcome
Specifications
Specialty
  • General Surgery
  • Otolaryngology
  • Plastic Surgery
  • Vascular Surgery
ID:
358
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #358: Patient-Centered Surgical Risk Assessment and Communication

Percentage of patients who underwent a non-emergency surgery who had their personalized risks of postoperative complications assessed by their surgical team prior to surgery using a clinical data-based, patient-specific risk calculator and who received personal discussion of those risks with the surgeon

Measure Type
  • Process
Specifications
Specialty
  • General Surgery
  • Orthopedic Surgery
  • Otolaryngology
  • Plastic Surgery
  • Thoracic Surgery
  • Urology
  • Vascular Surgery
ID:
360
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #360: Optimizing Patient Exposure to Ionizing Radiation: Count of Potential High Dose Radiation Imaging Studies: Computed Tomography (CT) and Cardiac Nuclear Medicine Studies

Percentage of computed tomography (CT) and cardiac nuclear medicine (myocardial perfusion studies) imaging reports for all patients, regardless of age, that document a count of known previous CT (any type of CT) and cardiac nuclear medicine (myocardial perfusion) studies that the patient has received in the 12-month period prior to the current study

Measure Type
  • Process
Specifications
Specialty
  • Diagnostic Radiology
ID:
364
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #364: Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow-up CT Imaging for Incidentally Detected Pulmonary Nodules According to Recommended Guidelines

Percentage of final reports for CT imaging studies with a finding of an incidental pulmonary nodule for patients aged 35 years and older that contain an impression or conclusion that includes a recommended interval and modality for follow-up (e.g., type of imaging or biopsy) or for no follow-up, and source of recommendations (e.g., guidelines such as Fleischner Society, American Lung Association, American College of Chest Physicians)

Measure Type
  • Process
Specifications
Specialty
  • Diagnostic Radiology
ID:
366
NQF:
eMeasure ID:
CMS136v10
High Priority:
No

2021 MIPS Measure #366: Follow-Up Care for Children Prescribed ADHD Medication (ADD)

Percentage of children 6-12 years of age and newly dispensed a medication for attention-deficit/hyperactivity disorder (ADHD) who had appropriate follow-up care. Two rates are reported.

a. Percentage of children who had one follow-up visit with a practitioner with prescribing authority during the 30-Day Initiation Phase.
b. Percentage of children who remained on ADHD medication for at least 210 days and who, in addition to the visit in the Initiation Phase, had at least two additional follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended.

Measure Type
  • Process
Specifications
Specialty
  • Mental/Behavioral Health
  • Pediatrics
ID:
370
NQF:
0710
eMeasure ID:
CMS159v9
High Priority:
Yes

2021 MIPS Measure #370: Depression Remission at Twelve Months

The percentage of adolescent patients 12 to 17 years of age and adult patients 18 years of age or older with major depression or dysthymia who reached remission 12 months (+/- 60 days) after an index event date

Measure Type
  • Outcome
Specifications
Specialty
  • Clinical Social Work
  • Family Medicine
  • Geriatrics
  • Internal Medicine
  • Mental/Behavioral Health
  • Pediatrics
ID:
374
NQF:
eMeasure ID:
CMS50v9
High Priority:
Yes

2021 MIPS Measure #374: Closing the Referral Loop: Receipt of Specialist Report

Percentage of patients with referrals, regardless of age, for which the referring provider receives a report from the provider to whom the patient was referred

Measure Type
  • Process
Specifications
Specialty
  • Allergy/Immunology
  • Cardiology
  • Dermatology
  • Endocrinology
  • Family Medicine
  • Gastroenterology
  • General Surgery
  • Internal Medicine
  • Interventional Radiology
  • Mental/Behavioral Health
  • Neurology
  • Obstetrics/Gynecology
  • Oncology/Hematology
  • Ophthalmology
  • Orthopedic Surgery
  • Otolaryngology
  • Physical Medicine
  • Preventive Medicine
  • Pulmonology
  • Rheumatology
  • Thoracic Surgery
  • Urology
  • Vascular Surgery
ID:
375
NQF:
eMeasure ID:
CMS66v9
High Priority:
Yes

2021 MIPS Measure #375: Functional Status Assessment for Total Knee Replacement

Percentage of patients 18 years of age and older who received an elective primary total knee arthroplasty (TKA) and completed a functional status assessment within 90 days prior to the surgery and in the 270-365 days after the surgery

Measure Type
  • Process
Specifications
Specialty
  • Orthopedic Surgery
ID:
376
NQF:
eMeasure ID:
CMS56v9
High Priority:
Yes

2021 MIPS Measure #376: Functional Status Assessment for Total Hip Replacement

Percentage of patients 18 years of age and older who received an elective primary total hip arthroplasty (THA) and completed a functional status assessment within 90 days prior to the surgery and in the 270-365 days after the surgery

Measure Type
  • Process
Specifications
Specialty
  • Orthopedic Surgery
ID:
377
NQF:
eMeasure ID:
CMS90v10
High Priority:
Yes

2021 MIPS Measure #377: Functional Status Assessments for Congestive Heart Failure

Percentage of patients 18 years of age and older with congestive heart failure who completed initial and follow-up patient-reported functional status assessments

Measure Type
  • Process
Specifications
Specialty
  • Family Medicine
  • Internal Medicine
ID:
378
NQF:
eMeasure ID:
CMS75v9
High Priority:
Yes

2021 MIPS Measure #378: Children Who Have Dental Decay or Cavities

Percentage of children, age 0-20 years, who have had tooth decay or cavities during the measurement period

Measure Type
  • Outcome
Specifications
Specialty
  • Dentistry
ID:
379
NQF:
eMeasure ID:
CMS74v10
High Priority:
No

2021 MIPS Measure #379: Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists

Percentage of children, age 0-20 years, who received a fluoride varnish application during the measurement period

Measure Type
  • Process
Specifications
Specialty
  • Dentistry
  • Pediatrics
ID:
382
NQF:
1365e
eMeasure ID:
CMS177v9
High Priority:
Yes

2021 MIPS Measure #382: Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment

Percentage of patient visits for those patients aged 6 through 17 years with a diagnosis of major depressive disorder with an assessment for suicide risk

Measure Type
  • Process
Specifications
Specialty
  • Clinical Social Work
  • Mental/Behavioral Health
  • Pediatrics
ID:
383
NQF:
1879
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #383: Adherence to Antipsychotic Medications For Individuals with Schizophrenia

Percentage of individuals at least 18 years of age as of the beginning of the performance period with schizophrenia or schizoaffective disorder who had at least two prescriptions filled for any antipsychotic medication and who had a Proportion of Days Covered (PDC) of at least 0.8 for antipsychotic medications during the performance period

Measure Type
  • Intermediate Outcome
Specifications
Specialty
  • Clinical Social Work
  • Family Medicine
  • Internal Medicine
  • Mental/Behavioral Health
ID:
384
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #384: Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to the Operating Room Within 90 Days of Surgery

Patients aged 18 years and older who had surgery for primary rhegmatogenous retinal detachment who did not require a return to the operating room within 90 days of surgery

Measure Type
  • Outcome
Specifications
Specialty
  • Ophthalmology
ID:
385
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #385: Adult Primary Rhegmatogenous Retinal Detachment Surgery: Visual Acuity Improvement Within 90 Days of Surgery

Patients aged 18 years and older who had surgery for primary rhegmatogenous retinal detachment and achieved an improvement in their visual acuity, from their preoperative level, within 90 days of surgery in the operative eye

Measure Type
  • Outcome
Specifications
Specialty
  • Ophthalmology
ID:
386
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #386: Amyotrophic Lateral Sclerosis (ALS) Patient Care Preferences

Percentage of patients diagnosed with Amyotrophic Lateral Sclerosis (ALS) who were offered assistance in planning for end of life issues (e.g., advance directives, invasive ventilation, hospice) at least once annually

Measure Type
  • Process
Specifications
Specialty
  • Neurology
ID:
387
NQF:
3060
eMeasure ID:
High Priority:
No

2021 MIPS Measure #387: Annual Hepatitis C Virus (HCV) Screening for Patients who are Active Injection Drug Users

Percentage of patients, regardless of age, who are active injection drug users who received screening for HCV infection within the 12-month reporting period

Measure Type
  • Process
Specifications
Specialty
  • Family Medicine
  • Internal Medicine
ID:
389
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #389: Cataract Surgery: Difference Between Planned and Final Refraction

Percentage of patients aged 18 years and older who had cataract surgery performed and who achieved a final refraction within +/- 1.0 diopters of their planned (target) refraction

Measure Type
  • Outcome
Specifications
Specialty
  • Ophthalmology
ID:
391
NQF:
0576
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #391: Follow-Up After Hospitalization for Mental Illness (FUH)

The percentage of discharges for patients 6 years of age and older who were hospitalized for treatment of selected mental illness or intentional self-harm diagnoses and who had a follow-up visit with a mental health practitioner. Two rates are submitted:

  • The percentage of discharges for which the patient received follow-up within 30 days after discharge
  • The percentage of discharges for which the patient received follow-up within 7 days after discharge
Measure Type
  • Process
Specifications
Specialty
  • Internal Medicine
  • Mental/Behavioral Health
  • Pediatrics
ID:
392
NQF:
2474
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #392: Cardiac Tamponade and/or Pericardiocentesis Following Atrial Fibrillation Ablation

Rate of cardiac tamponade and/or pericardiocentesis following atrial fibrillation ablation. This measure is submitted as four rates stratified by age and gender:

  • Submission Age Criteria 1: Females 18-64 years of age
  • Submission Age Criteria 2: Males 18-64 years of age
  • Submission Age Criteria 3: Females 65 years of age and older
  • Submission Age Criteria 4: Males 65 years of age and older
Measure Type
  • Outcome
Specifications
Specialty
  • Electrophysiology Cardiac Specialist
ID:
393
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #393: Infection within 180 Days of Cardiac Implantable Electronic Device (CIED) Implantation, Replacement, or Revision

Infection rate following CIED device implantation, replacement, or revision

Measure Type
  • Outcome
Specifications
Specialty
  • Electrophysiology Cardiac Specialist
ID:
394
NQF:
1407
eMeasure ID:
High Priority:
No

2021 MIPS Measure #394: Immunizations for Adolescents

The percentage of adolescents 13 years of age who had one dose of meningococcal vaccine (serogroups A, C, W, Y), one tetanus, diphtheria toxoids and acellular pertussis (Tdap) vaccine, and have completed the human papillomavirus (HPV) vaccine series by their 13th birthday.

Measure Type
  • Process
Specifications
Specialty
  • Family Medicine
  • Pediatrics
ID:
395
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #395: Lung Cancer Reporting (Biopsy/Cytology Specimens)

Pathology reports based on biopsy and/or cytology specimens with a diagnosis of primary non-small cell lung cancer classified into specific histologic type or classified as non-small cell lung cancer not otherwise specified (NSCLC-NOS) with an explanation included in the pathology report

Measure Type
  • Process
Specifications
Specialty
  • Pathology
ID:
396
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #396: Lung Cancer Reporting (Resection Specimens)

Pathology reports based on resection specimens with a diagnosis of primary lung carcinoma that include the pT category, pN category and for non-small cell lung cancer (NSCLC), histologic type

Measure Type
  • Process
Specifications
Specialty
  • Pathology
ID:
397
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #397: Melanoma Reporting

Pathology reports for primary malignant cutaneous melanoma that include the pT category and a statement on thickness, ulceration and mitotic rate

Measure Type
  • Process
Specifications
Specialty
  • Pathology
ID:
398
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #398: Optimal Asthma Control

Composite measure of the percentage of pediatric and adult patients whose asthma is well-controlled as demonstrated by one of three age appropriate patient reported outcome tools and not at risk for exacerbation

Measure Type
  • Outcome
Specifications
Specialty
  • Allergy/Immunology
  • Family Medicine
  • Internal Medicine
  • Otolaryngology
  • Pediatrics
  • Pulmonology
ID:
400
NQF:
3059
eMeasure ID:
High Priority:
No

2021 MIPS Measure #400: One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk

Percentage of patients aged 18 years and older with one or more of the following: a history of injection drug use, receipt of a blood transfusion prior to 1992, receiving maintenance hemodialysis, OR birthdate in the years 1945- 1965 who received one-time screening for hepatitis C virus (HCV) infection

Measure Type
  • Process
Specifications
Specialty
  • Family Medicine
  • Internal Medicine
  • Nephrology
ID:
401
NQF:
eMeasure ID:
High Priority:
No

2021 MIPS Measure #401: Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis

Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis who underwent imaging with either ultrasound, contrast enhanced CT or MRI for hepatocellular carcinoma (HCC) at least once within the 12-month submission period

Measure Type
  • Process
Specifications
Specialty
  • Family Medicine
  • Gastroenterology
  • Internal Medicine
ID:
402
NQF:
2803
eMeasure ID:
High Priority:
No

2021 MIPS Measure #402: Tobacco Use and Help with Quitting Among Adolescents

The percentage of adolescents 12 to 20 years of age with a primary care visit during the measurement year for whom tobacco use status was documented and received help with quitting if identified as a tobacco user

Measure Type
  • Process
Specifications
Specialty
  • Allergy/Immunology
  • Cardiology
  • Clinical Social Work
  • Dermatology
  • Family Medicine
  • Gastroenterology
  • General Surgery
  • Internal Medicine
  • Mental/Behavioral Health
  • Neurology
  • Obstetrics/Gynecology
  • Oncology/Hematology
  • Orthopedic Surgery
  • Otolaryngology
  • Pediatrics
  • Physical Medicine
  • Preventive Medicine
  • Rheumatology
  • Thoracic Surgery
  • Urgent Care
  • Vascular Surgery
ID:
404
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #404: Anesthesiology Smoking Abstinence

The percentage of current smokers who abstain from cigarettes prior to anesthesia on the day of elective surgery or procedure

Measure Type
  • Intermediate Outcome
Specifications
Specialty
  • Anesthesiology
ID:
405
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #405: Appropriate Follow-up Imaging for Incidental Abdominal Lesions

Percentage of final reports for imaging studies for patients aged 18 years and older with one or more of the following noted incidentally with a specific recommendation for no follow‐up imaging recommended based on radiological findings:

  • Cystic renal lesion that is simple appearing* (Bosniak I or II)
  • Adrenal lesion less than or equal to 1.0 cm
  • Adrenal lesion greater than 1.0 cm but less than or equal to 4.0 cm classified as likely benign or diagnostic benign by unenhanced CT or washout protocol CT, or MRI with in- and opposed-phase sequences or other equivalent institutional imaging protocols
Measure Type
  • Process
Specifications
Specialty
  • Diagnostic Radiology
ID:
406
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #406: Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients

Percentage of final reports for computed tomography (CT), CT angiography (CTA) or magnetic resonance imaging (MRI) or magnetic resonance angiogram (MRA) studies of the chest or neck for patients aged 18 years and older with no known thyroid disease with a thyroid nodule < 1.0 cm noted incidentally with follow-up imaging recommended

Measure Type
  • Process
Specifications
Specialty
  • Diagnostic Radiology
ID:
409
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #409: Clinical Outcome Post Endovascular Stroke Treatment

Percentage of patients with a mRs score of 0 to 2 at 90 days following endovascular stroke intervention

Measure Type
  • Outcome
Specifications
Specialty
  • Interventional Radiology
  • Neurosurgery
ID:
410
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #410: Psoriasis: Clinical Response to Oral Systemic or Biologic Medications

Percentage of psoriasis vulgaris patients receiving systemic medication who meet minimal physician-or patient- reported disease activity levels. It is implied that establishment and maintenance of an established minimum level of disease control as measured by physician-and/or patient-reported outcomes will increase patient satisfaction with and adherence to treatment

Measure Type
  • Outcome
Specifications
Specialty
  • Dermatology
ID:
413
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #413: Door to Puncture Time for Endovascular Stroke Treatment

Percentage of patients undergoing endovascular stroke treatment who have a door to puncture time of less than two hours

Measure Type
  • Intermediate Outcome
Specifications
Specialty
  • Interventional Radiology
  • Neurosurgery
ID:
415
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #415: Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older

Percentage of emergency department visits for patients aged 18 years and older who presented with a minor blunt head trauma who had a head CT for trauma ordered by an emergency care provider who have an indication for a head CT

Measure Type
  • Efficiency
Specifications
Specialty
  • Emergency Medicine
ID:
416
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #416: Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 2 Through 17 Years

Percentage of emergency department visits for patients aged 2 through 17 years who presented with a minor blunt head trauma who had a head CT for trauma ordered by an emergency care provider who are classified as low risk according to the Pediatric Emergency Care Applied Research Network (PECARN) prediction rules for traumatic brain injury

Measure Type
  • Efficiency
Specifications
Specialty
  • Emergency Medicine
ID:
418
NQF:
0053
eMeasure ID:
High Priority:
No

2021 MIPS Measure #418: Osteoporosis Management in Women Who Had a Fracture

The percentage of women age 50-85 who suffered a fracture in the six months prior to the performance period through June 30 of the performance period and who either had a bone mineral density test or received a prescription for a drug to treat osteoporosis in the six months after the fracture

Measure Type
  • Process
Specifications
Specialty
  • Endocrinology
  • Family Medicine
  • Internal Medicine
  • Obstetrics/Gynecology
  • Orthopedic Surgery
ID:
419
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #419: Overuse of Imaging for the Evaluation of Primary Headache

Percentage of patients for whom imaging of the head (CT or MRI) is obtained for the evaluation of primary headache when clinical indications are not present

Measure Type
  • Process
Specifications
Specialty
  • Neurology
ID:
420
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #420: Varicose Vein Treatment with Saphenous Ablation: Outcome Survey

Percentage of patients treated for varicose veins (CEAP C2-S) who are treated with saphenous ablation (with or without adjunctive tributary treatment) that report an improvement on a disease specific patient reported outcome survey instrument after treatment

Measure Type
  • Outcome
Specifications
Specialty
  • Interventional Radiology
  • Vascular Surgery
ID:
421
NQF:
eMeasure ID:
High Priority:
No

2021 MIPS Measure #421: Appropriate Assessment of Retrievable Inferior Vena Cava (IVC) Filters for Removal

Percentage of patients in whom a retrievable IVC filter is placed who, within 3 months post-placement, have a documented assessment for the appropriateness of continued filtration, device removal, or the inability to contact the patient with at least two attempts

Measure Type
  • Process
Specifications
Specialty
  • Interventional Radiology
ID:
422
NQF:
2063
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #422: Performing Cystoscopy at the Time of Hysterectomy for Pelvic Organ Prolapse to Detect Lower Urinary Tract Injury

Percentage of patients who undergo cystoscopy to evaluate for lower urinary tract injury at the time of hysterectomy for pelvic organ prolapse

Measure Type
  • Process
Specifications
Specialty
  • Obstetrics/Gynecology
ID:
424
NQF:
2671
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #424: Perioperative Temperature Management

Percentage of patients, regardless of age, who undergo surgical or therapeutic procedures under general or neuraxial anesthesia of 60 minutes duration or longer for whom at least one body temperature greater than or equal to 35.5 degrees Celsius (or 95.9 degrees Fahrenheit) was achieved within the 30 minutes immediately before or the 15 minutes immediately after anesthesia end time

Measure Type
  • Outcome
Specifications
Specialty
  • Anesthesiology
ID:
425
NQF:
eMeasure ID:
High Priority:
No

2021 MIPS Measure #425: Photodocumentation of Cecal Intubation

The rate of screening and surveillance colonoscopies for which photodocumentation of at least two landmarks of cecal intubation is performed to establish a complete examination

Measure Type
  • Process
Specifications
Specialty
  • Gastroenterology
ID:
429
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #429: Pelvic Organ Prolapse: Preoperative Screening for Uterine Malignancy

Percentage of patients who are screened for uterine malignancy prior to vaginal closure or obliterative surgery for pelvic organ prolapse

Measure Type
  • Process
Specifications
Specialty
  • Obstetrics/Gynecology
  • Urology
ID:
430
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #430: Prevention of Post-Operative Nausea and Vomiting (PONV) – Combination Therapy

Percentage of patients, aged 18 years and older, who undergo a procedure under an inhalational general anesthetic, AND who have three or more risk factors for post-operative nausea and vomiting (PONV), who receive combination therapy consisting of at least two prophylactic pharmacologic anti-emetic agents of different classes preoperatively and/or intraoperatively

Measure Type
  • Process
Specifications
Specialty
  • Anesthesiology
ID:
431
NQF:
2152
eMeasure ID:
High Priority:
No

2021 MIPS Measure #431: Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling

Percentage of patients aged 18 years and older who were screened for unhealthy alcohol use using a systematic screening method at least once within the last 12 months AND who received brief counseling if identified as an unhealthy alcohol user

Measure Type
  • Process
Specifications
Specialty
  • Cardiology
  • Clinical Social Work
  • Family Medicine
  • Gastroenterology
  • Internal Medicine
  • Mental/Behavioral Health
  • Neurology
  • Nutrition/Dietician
  • Obstetrics/Gynecology
  • Oncology/Hematology
  • Otolaryngology
  • Physical Medicine
  • Preventive Medicine
  • Pulmonology
  • Urgent Care
  • Urology
ID:
432
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #432: Proportion of Patients Sustaining a Bladder Injury at the Time of any Pelvic Organ Prolapse Repair

Percentage of patients undergoing pelvic organ prolapse repairs who sustain an injury to the bladder recognized either during or within 30 days after surgery.

Measure Type
  • Outcome
Specifications
Specialty
  • Obstetrics/Gynecology
  • Urology
ID:
433
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #433: Proportion of Patients Sustaining a Bowel Injury at the time of any Pelvic Organ Prolapse Repair

Percentage of patients undergoing surgical repair of pelvic organ prolapse that is complicated by a bowel injury at the time of index surgery that is recognized intraoperatively or within 30 days after surgery.

Measure Type
  • Outcome
Specifications
Specialty
  • Obstetrics/Gynecology
  • Urology
ID:
434
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #434: Proportion of Patients Sustaining a Ureter Injury at the Time of Pelvic Organ Prolapse Repair

Percentage of patients undergoing pelvic organ prolapse repairs who sustain an injury to the ureter recognized either during or within 30 days after surgery.

Measure Type
  • Outcome
Specifications
Specialty
  • Obstetrics/Gynecology
  • Urology
ID:
436
NQF:
eMeasure ID:
High Priority:
No

2021 MIPS Measure #436: Radiation Consideration for Adult CT: Utilization of Dose Lowering Techniques

Percentage of final reports for patients aged 18 years and older undergoing computed tomography (CT) with documentation that one or more of the following dose reduction techniques were used

  • Automated exposure control
  • Adjustment of the mA and/or kV according to patient size
  • Use of iterative reconstruction technique
Measure Type
  • Process
Specifications
Specialty
  • Diagnostic Radiology
ID:
438
NQF:
eMeasure ID:
CMS347v4
High Priority:
No

2021 MIPS Measure #438: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease

Percentage of the following patients - all considered at high risk of cardiovascular events - who were prescribed or were on statin therapy during the measurement period:

  • Adults aged ≥ 21 years who were previously diagnosed with or currently have an active diagnosisof clinical atherosclerotic cardiovascular disease (ASCVD); OR
  • Adults aged ≥ 21 years who have ever had a fasting or direct low-density lipoprotein cholesterol (LDL-C) level ≥ 190 mg/dL or were previously diagnosed with or currently have an active diagnosis of familial or pure hypercholesterolemia; OR
  • Adults aged 40-75 years with a diagnosis of diabetes with a fasting or direct LDL-C level of 70-189 mg/dL
Measure Type
  • Process
Specifications
Specialty
  • Cardiology
  • Endocrinology
  • Family Medicine
  • Internal Medicine
  • Preventive Medicine
ID:
439
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #439: Age Appropriate Screening Colonoscopy

The percentage of screening colonoscopies performed in patients greater than or equal to 86 years of age from January 1 to December 31

Measure Type
  • Efficiency
Specifications
Specialty
  • Gastroenterology
ID:
440
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #440: Skin Cancer: Biopsy Reporting Time – Pathologist to Clinician

Percentage of biopsies with a diagnosis of cutaneous Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC), or melanoma (including in situ disease) in which the pathologist communicates results to the clinician within 7 days from the time when the tissue specimen was received by the pathologist

Measure Type
  • Process
Specifications
Specialty
  • Dermatology
  • Pathology
ID:
441
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #441: Ischemic Vascular Disease (IVD) All or None Outcome Measure (Optimal Control)

The IVD All-or-None Measure is one outcome measure (optimal control). The measure contains four goals. All four goals within a measure must be reached in order to meet that measure. The numerator for the all-or-none measure should be collected from the organization's total IVD denominator. All-or-None Outcome Measure (Optimal Control) - Using the IVD denominator optimal results include:

  • Most recent blood pressure (BP) measurement is less than or equal to 140/90 mm Hg --AND
  • Most recent tobacco status is Tobacco Free -- AND
  • Daily Aspirin or Other Antiplatelet Unless Contraindicated -- AND
  • Statin Use Unless Contraindicated
Measure Type
  • Intermediate Outcome
Specifications
Specialty
  • Cardiology
  • Family Medicine
  • Internal Medicine
  • Vascular Surgery
ID:
443
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #443: Non-Recommended Cervical Cancer Screening in Adolescent Females

The percentage of adolescent females 16–20 years of age who were screened unnecessarily for cervical cancer

Measure Type
  • Process
Specifications
Specialty
  • Family Medicine
  • Internal Medicine
  • Obstetrics/Gynecology
ID:
444
NQF:
1799
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #444: Medication Management for People with Asthma

The percentage of patients 5-64 years of age during the performance period who were identified as having persistent asthma and were dispensed appropriate medications that they remained on for at least 75% of their treatment period

Measure Type
  • Process
Specifications
Specialty
  • Allergy/Immunology
  • Family Medicine
  • Internal Medicine
  • Pediatrics
  • Pulmonology
ID:
445
NQF:
0119
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #445: Risk-Adjusted Operative Mortality for Coronary Artery Bypass Graft (CABG)

Percent of patients aged 18 years and older undergoing isolated CABG who die, including both all deaths occurring during the hospitalization in which the CABG was performed, even if after 30 days, and those deaths occurring after discharge from the hospital, but within 30 days of the procedure

Measure Type
  • Outcome
Specifications
Specialty
  • Thoracic Surgery
ID:
448
NQF:
0567
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #448: Appropriate Workup Prior to Endometrial Ablation

Percentage of patients, aged 18 years and older, who undergo endometrial sampling or hysteroscopy with biopsy and results are documented before undergoing an endometrial ablation

Measure Type
  • Process
Specifications
Specialty
  • Obstetrics/Gynecology
ID:
450
NQF:
1858
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #450: Appropriate Treatment for Patients with Stage I (T1c) – III HER2 Positive Breast Cancer

Percentage of female patients aged 18 to 70 with stage I (T1c) – III HER2 positive breast cancer for whom appropriate treatment is initiated

Measure Type
  • Process
Specifications
Specialty
  • Oncology/Hematology
ID:
451
NQF:
1859
eMeasure ID:
High Priority:
No

2021 MIPS Measure #451: KRAS Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy

Percentage of adult patients (aged 18 or over) with metastatic colorectal cancer who receive anti-epidermal growth factor receptor monoclonal antibody therapy for whom RAS (KRAS and NRAS) gene mutation testing was performed

Measure Type
  • Process
Specifications
Specialty
  • Oncology/Hematology
ID:
452
NQF:
1860
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #452: Patients with Metastatic Colorectal Cancer and RAS (KRAS or NRAS) Gene Mutation Spared Treatment with Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies

Percentage of adult patients (aged 18 or over) with metastatic colorectal cancer and RAS (KRAS or NRAS) gene mutation spared treatment with anti-EGFR monoclonal antibodies.

Measure Type
  • Process
Specifications
Specialty
  • Oncology/Hematology
ID:
453
NQF:
0210
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #453: Percentage of Patients who Died from Cancer Receiving Chemotherapy in the Last 14 Days of Life (lower score – better)

Percentage of patients who died from cancer receiving chemotherapy in the last 14 days of life

Measure Type
  • Process
Specifications
Specialty
  • Oncology/Hematology
ID:
455
NQF:
0213
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #455: Percentage of Patients who Died from Cancer Admitted to the Intensive Care Unit (ICU) in the Last 30 Days of Life (lower score – better)

Percentage of patients who died from cancer admitted to the ICU in the last 30 days of life

Measure Type
  • Outcome
Specifications
Specialty
  • Geriatrics
  • Oncology/Hematology
ID:
457
NQF:
0216
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #457: Percentage of Patients who Died from Cancer Admitted to Hospice for Less than 3 Days (lower score – better)

Percentage of patients who died from cancer, and admitted to hospice and spent less than 3 days there

Measure Type
  • Outcome
Specifications
Specialty
  • Oncology/Hematology
ID:
459
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #459: Back Pain After Lumbar Discectomy/Laminectomy

For patients 18 years of age or older who had a lumbar discectomy/laminectomy procedure, back pain is rated by the patients as less than or equal to 3.0 OR an improvement of 5.0 points or greater on the Visual Analog Scale (VAS) Pain scale at three months (6 to 20 weeks) postoperativelyhttps://data.mncm.org/help/faq_documents/0000/0732/MNCM_Visual_Analog_Pain_Scale_7-16-2013.pdf

Measure Type
  • Outcome
Specifications
Specialty
  • Neurosurgery
  • Orthopedic Surgery
ID:
460
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #460: Back Pain After Lumbar Fusion

For patients 18 years of age or older who had a lumbar fusion procedure, back pain is rated by the patient as less than or equal to 3.0 OR an improvement of 5.0 points or greater on the Visual Analog Scale (VAS) Pain* scale at one year (9 to 15 months) postoperatively
* hereafter referred to as VAS Pain

Measure Type
  • Outcome
Specifications
Specialty
  • Neurosurgery
  • Orthopedic Surgery
ID:
461
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #461: Leg Pain After Lumbar Discectomy/ Laminectomy

For patients 18 years of age or older who had a lumbar discectomy/laminectomy procedure, leg pain is rated by the patient as less than or equal to 3.0 OR an improvement of 5.0 points or greater on the VAS Pain scale at three months (6 to 20 weeks) postoperatively

Measure Type
  • Outcome
Specifications
Specialty
  • Neurosurgery
  • Orthopedic Surgery
ID:
462
NQF:
eMeasure ID:
CMS645v4
High Priority:
No

2021 MIPS Measure #462: Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy

Patients determined as having prostate cancer who are currently starting or undergoing androgen deprivation therapy (ADT), for an anticipated period of 12 months or greater and who receive an initial bone density evaluation. The bone density evaluation must be prior to the start of ADT or within 3 months of the start of ADT.

Measure Type
  • Process
Specifications
Specialty
  • Endocrinology
  • Oncology/Hematology
  • Urology
ID:
463
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #463: Prevention of Post-Operative Vomiting (POV) – Combination Therapy (Pediatrics)

Percentage of patients aged 3 through 17 years, who undergo a procedure under general anesthesia in which an inhalational anesthetic is used for maintenance AND who have two or more risk factors for post-operative vomiting (POV), who receive combination therapy consisting of at least two prophylactic pharmacologic anti-emetic agents of different classes preoperatively and/or intraoperatively

Measure Type
  • Process
Specifications
Specialty
  • Anesthesiology
ID:
464
NQF:
0657
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #464: Otitis Media with Effusion: Systemic Antimicrobials - Avoidance of Inappropriate Use

Percentage of patients aged 2 months through 12 years with a diagnosis of OME who were not prescribed systemic antimicrobials

Measure Type
  • Process
Specifications
Specialty
  • Family Medicine
  • Otolaryngology
  • Pediatrics
  • Urgent Care
ID:
465
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #465: Uterine Artery Embolization Technique: Documentation of Angiographic Endpoints and Interrogation of Ovarian Arteries

The percentage of patients with documentation of angiographic endpoints of embolization AND the documentation of embolization strategies in the presence of unilateral or bilateral absent uterine arteries

Measure Type
  • Process
Specifications
Specialty
  • Interventional Radiology
ID:
468
NQF:
3175
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #468: Continuity of Pharmacotherapy for Opioid Use Disorder (OUD)

Percentage of adults aged 18 years and older with pharmacotherapy for opioid use disorder (OUD) who have at least 180 days of continuous treatment

Measure Type
  • Process
Specifications
Specialty
  • Family Medicine
  • Internal Medicine
  • Mental/Behavioral Health
  • Physical Medicine
ID:
469
NQF:
2643
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #469: Functional Status After Lumbar Fusion

For patients 18 years of age and older who had a lumbar fusion procedure, functional status is rated by the patient as less than or equal to 22 OR a change of 30 points or greater on the Oswestry Disability Index (ODI version 2.1a)* at one year (9 to 15 months) postoperatively
* hereafter referred to as ODI

Measure Type
  • Outcome
Specifications
Specialty
  • Neurosurgery
  • Orthopedic Surgery
ID:
470
NQF:
2653
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #470: Functional Status After Primary Total Knee Replacement

For patients age 18 and older who had a primary total knee replacement procedure, functional status is rated by the patient as greater than or equal to 37 on the Oxford Knee Score (OKS) or a 71 or greater on the KOOS, JR. tool at one year (9 to 15 months) postoperatively

Measure Type
  • Outcome
Specifications
Specialty
  • Orthopedic Surgery
ID:
471
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #471: Functional Status After Lumbar Discectomy/Laminectomy

For patients age 18 and older who had lumbar discectomy/laminectomy procedure, functional status is rated by the patient as less than or equal to 22 OR a change of 30 points or greater on the Oswestry Disability Index (ODI version 2.1a) * at three months (6 to 20 weeks) postoperatively
* hereafter referred to as ODI

Measure Type
  • Outcome
Specifications
Specialty
  • Neurosurgery
  • Orthopedic Surgery
ID:
472
NQF:
eMeasure ID:
CMS249v3
High Priority:
Yes

2021 MIPS Measure #472: Appropriate Use of DXA Scans in Women Under 65 Years Who Do Not Meet the Risk Factor Profile for Osteoporotic Fracture

Percentage of female patients 50 to 64 years of age without select risk factors for osteoporotic fracture who received an order for a dual-energy x-ray absorptiometry (DXA) scan during the measurement period.

Measure Type
  • Process
Specifications
Specialty
  • Family Medicine
  • Internal Medicine
  • Obstetrics/Gynecology
ID:
473
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #473: Leg Pain After Lumbar Fusion

For patients 18 years of age or older who had a lumbar fusion procedure, leg pain is rated by the patient as less than or equal to 3.0 OR an improvement of 5.0 points or greater on the Visual Analog Scale (VAS) Pain* scale at one year (9 to 15 months) postoperatively
* hereafter referred to as VAS Pain

Measure Type
  • Outcome
Specifications
Specialty
  • Neurosurgery
  • Orthopedic Surgery
ID:
475
NQF:
eMeasure ID:
CMS349v3
High Priority:
No

2021 MIPS Measure #475: HIV Screening

Percentage of patients aged 15-65 at the start of the measurement period who were between 15-65 years old when tested for HIV

Measure Type
  • Process
Specifications
Specialty
  • Family Medicine
  • Infectious Disease
  • Internal Medicine
  • Obstetrics/Gynecology
  • Preventive Medicine
ID:
476
NQF:
eMeasure ID:
CMS771v2
High Priority:
Yes

2021 MIPS Measure #476: Urinary Symptom Score Change 6-12 Months After Diagnosis of Benign Prostatic Hyperplasia

Percentage of patients with an office visit within the measurement period and with a new diagnosis of clinically significant Benign Prostatic Hyperplasia who have International Prostate Symptoms Score (IPSS) or American Urological Association (AUA) Symptom Index (SI) documented at time of diagnosis and again 6-12 months later with an improvement of 3 points.

Measure Type
  • Outcome
Specifications
Specialty
  • Geriatrics
  • Urology
ID:
477
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #477: Multimodal Pain Management

Percentage of patients, aged 18 years and older, undergoing selected surgical procedures that were managed with multimodal pain medicine

Measure Type
  • Process
Specifications
Specialty
  • Anesthesiology
ID:
478
NQF:
eMeasure ID:
High Priority:
Yes

2021 MIPS Measure #478: Functional Status Change for Patients with Neck Impairments

This is a patient-reported outcome measure of risk-adjusted change in functional status for patients aged 14 years+ with neck impairments. The change in functional status (FS) is assessed using the FOTO Neck FS patient-reported outcome measure (PROM). The measure is adjusted to patient characteristics known to be associated with FS outcomes (risk-adjusted) and used as a performance measure at the patient level, at the individual clinician level, and at the clinic level to assess quality. The measure is available as a computer adaptive test, for reduced patient burden, or a short form (static/paper-pencil).

Measure Type
  • Outcome
Specifications
Specialty
  • Chiropractic Medicine
  • Orthopedic Surgery
  • Physical Therapy/Occupational Therapy

Register with MDinteractive